No Data
Executive Reshuffles: JPM, QCOM, DVN and LTC
Assertio Announces Results Of A Clinical Trial Investigating The Utility Of Rolvedon Injection When Dosed The Same Day Of Chemotherapy For Patients With Early Stage Breast Cancer
Express News | Assertio Holdings Inc - Rolvedon Shows 1.8 Days to Neutrophil Count Recovery
Express News | Assertio Holdings Inc - No New Safety Signals Identified in Rolvedon Trial
Express News | Assertio Announces Results of Rolvedon® (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study
Assertio: Schwichtenberg to Identify Synergies, Innovative Strategies, New Rev Streams >ASRT